CJC-1295 without DAC (Modified GRF 1-29) record · updated 21h ago

Muscle & body compMetabolic & appetiteGrade B · human evidenceResearch use only

All 2 studies Jump to the evidence Compare

What is CJC-1295 without DAC (Modified GRF 1-29) used for?

CJC-1295 without DAC (Modified GRF 1-29) is a short-acting GHRH analog studied for its ability to stimulate pulsatile growth hormone release from the pituitary.

How it works: GHRH (1–29) analog, modified

Primarily researched for · Muscle & body compRoute · Subcutaneous injection

Development stage

where CJC-1295 without DAC (Modified GRF 1-29) sits between preclinical work and regulatory approval

1Current
Preclinical
Animal / in-vitro work
2Not reached
Phase 1
Safety in humans
3Not reached
Phase 2
Efficacy signal
4Not reached
Phase 3
Confirmatory trials
5Not reached
Approved
Cleared by a regulator

Stage is inferred from the highest trial phase in the indexed corpus and 17 registered trials. It describes the research record, not a recommendation.

Identity

NameCJC-1295 without DAC (Modified GRF 1-29)

Chain length—

Molecular weight—

Formula—

Structure type—

ClassMuscle

Research levelPreclinical

Discovered byCurated master list · 2026

Pharmacology

MechanismGHRH (1–29) analog, modified

RouteSubcutaneous injection

Half-life~30 min

Time to peak—

Duration—

Extraction confidence0.60

Effect profile · 0–5

These seven scores are generated by the Librarian — an autonomous agent running GPT-4o over the indexed studies, trials and label data for this compound. No human assigns them and no community vote moves them. Last recomputed Aug 20, 2026. How this works →

Research stats

Total studies2

Human / animal / cellular1 / 1 / 0

Highest trial phasePreclinical

Years covered2026

Latest study6d ago

Publication history

20262026

Research funding

—no NIH grants found

Safety signals

FAERS reportsnone recorded

Serious AEs in animal work—

Community reports—

Positive —Neutral —Negative —

Records

ChEMBL ClinicalTrials.gov DrugBank Google Scholar PubChem PubMed · 2 Semantic Scholar UniProt

Study register

2 rowsOpen in the library →

SortDate added ↓Publication year Evidence type Summary depth

Study	Type	Year	Summary depth
An orthogonal transcription system enables high-efficiency rescue of measles virus-based vaccine vectors against multiple pathogens. FindingRescue efficiency enhanced by more than 50-fold.	Animal	2026	Full text read0.80
A Step-Up Underwater Endoscopic Mucosal Resection Strategy with Rescue Underwater Injection Endoscopic Mucosal Resection for Non-Pedunculated Colorectal Lesions. FindingEn bloc resection achieved in 100% of lesions.	Human	2026	Full text read0.80

What people are saying

anecdotal · not evidence

Unverified first-hand accounts from public forums. These are not studies: nobody checked what was taken, whether it was what the label said, or what else was going on. They count for nothing in the evidence grade above and are shown because a reader searching CJC-1295 without DAC (Modified GRF 1-29) will meet them anyway, and meeting them next to a graded evidence base is better than meeting them alone.

Community collection has not run yet, so this is an empty shelf rather than a quiet one — nothing has been read, and no conclusion about how much CJC-1295 without DAC (Modified GRF 1-29) is discussed should be drawn from it.